2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Sunday, November 10, 2019

9:00AM-11:00AM: Abstract Number: 325

Frailty and Sarcopenia in Inflammatory Rheumatic Disease

Measures Of Healthcare Quality Poster I: Testing, Screening, & Treating

9:00AM-11:00AM: Abstract Number: 558

Frequency and Characteristics of Inflammatory Bowel Disease in Spondyloarthritis with Biological Therapy: Study of 270 Patients from the Same Center

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 411

Frequency and Staining Patterns of Antinuclear Antibodies in Myositis Patients Without Known Myositis-specific Autoantibodies

Muscle Biology, Myositis & Myopathies Poster I

9:00AM-11:00AM: Abstract Number: 361

Frequency of Allopurinol Dose Reduction in Hospitalized Patients with Gout Flares

Metabolic & Crystal Arthropathies Poster I: Clinical

9:00AM-11:00AM: Abstract Number: 408

Frequency of Concomitant Non-aminoacyl-transfer-RNA Synthetase Autoantibodies in Patients with Antisynthetase Syndrome

Muscle Biology, Myositis & Myopathies Poster I

9:00AM-11:00AM: Abstract Number: 600

Frequency of Disease Flares Under Long-Term Anti-TNF Therapy in Patients with Early Axial Spondyloarthritis: Results from the Etanercept versus Sulfasalazine in Early Axial Spondyloarthritis Trial (ESTHER)

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 265

Frequency of Performing Anti dsDNA Antibody in an ANA Negative Patient with Clinical Suspicion of SLE in a Single Centre Trial Before and After the Publication of National Guideline

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 281

Frequency of Ultrasound Features of Knee Osteoarthritis and Their Association with Radiographic Features and Symptoms in a Community-Based Cohort

Imaging Of Rheumatic Diseases Poster I

9:00AM-11:00AM: Abstract Number: 264

Gaps in Patient Safety Performance in Patients with Immunosuppressive Therapy: Results of Screening for Infections and Vaccination Status in a Large Real-life Cohort

Health Services Research Poster I – ACR/ARP

9:00AM-11:00AM: Abstract Number: 577

Gender Contrasts in Patient Reported Outcomes Don’t Alter the Disease Activity Score in Axial Spondyloarthritis Patients

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 629

Gender Differences in Comorbidities and Treatment Utilization Among Ankylosing Spondylitis Patients Initiating a Biologic in a Real-World Setting

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

9:00AM-11:00AM: Abstract Number: 776

Genetic Signatures Support Inflammation Driven Fibrosis in Localized Scleroderma

Pediatric Rheumatology – ePoster I: Basic Science, Biomarkers, & Sclerodermic Fever

9:00AM-11:00AM: Abstract Number: 416

Global Management of Patients with Knee Osteoarthritis Begins with Quality of Life Assessment: A Systematic Review

Patient Outcomes, Preferences, & Attitudes Poster I: Patient Reported Outcomes

9:00AM-11:00AM: Abstract Number: 228

Good Pain, Bad Pain: Illness Perception and Physicians Attitude Towards Rheumatoid Arthritis and Fibromyalgia Patients

Fibromyalgia & Other Clinical Pain Syndromes Poster

9:00AM-11:00AM: Abstract Number: 356

Gout Flares Become Infrequent During a Treat-to-target Strategy over One Year: Data from the NOR-Gout Study

Metabolic & Crystal Arthropathies Poster I: Clinical

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].